Thomas Werner

Thomas Werner is Vice Chairman at Basilea Pharmaceutica AG since 2018, Chairman at Pharmathen SA, Director at SuppreMol GmbH, and Trustee at Robert Koch Stiftung eV since 2010.
Former roles include President & Chief Executive Officer at Cerecin, Inc. in 2010; Vice Chairman at Vectura Group Ltd. from 2019 to 2021; Chairman-Supervisory Board at 4SC AG from 2009 to 2014; Chairman at Fertin Pharma A from 2017 to 2019; Executive Chairman at PharmaSwiss SA in 2011; Non-Executive Chairman at CM&D Pharma Ltd.; Chairman at Claudio BidCo A; Director at RIEMSER Pharma GmbH; Director at American Chamber of Commerce in Germany eV; Managing Director & Senior Vice President at GlaxoSmithKline GmbH & Co. KG.
from 2001 to 2008; Managing Director at Central Europe GmbH; Director at BSN medical GmbH; Managing Director & Director at Glaxo Wellcome GmbH & Co. KG from 1997 to 2000; Managing Director at Bristol-Myers Squibb GmbH & Co. KGaA from 1983 to 1997; Managing Director at Convatec (Germany) GmbH; Director at Robert Koch Foundation; Senior Independent Non-Executive Director at SkyePharma Plc from 2009 to 2021; Member-Supervisory Board at MediGene AG from 2010 to 2013; Investment Committee at Seventure Partners SA from 2015 to 2021; Trustee at Paul Ehrlich-Foundation.
Education includes a doctorate from the University of Gottingen.